Cargando…

Long-term efficacy and safety of adalimumab in 4-12 year old patients with juvenile idiopathic arthritis

Detalles Bibliográficos
Autores principales:	Ruperto, N, Lovell, DJ, Reiff, A, Gamir, M, Higgins, G, Koné-Paut, I, Jones, OY, Chalom, E, Ilowite, N, Wouters, C, McIlraith, MJ, Liu, S, Kupper, H, Giannini, EH, Martini, A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3194421/ http://dx.doi.org/10.1186/1546-0096-9-S1-O26

Ejemplares similares

PReS-FINAL-2001: The impact of adalimumab on growth in patients with juvenile idiopathic arthritis
por: Ruperto, N, et al.
Publicado: (2013)

7.4 Improvements in individual disease components are sustained with long-term adalimumab therapy for polyarticular Juvenile Idiopathic Arthritis
por: Ruperto, N, et al.
Publicado: (2008)

7.5 Safety data from over 1,200 patients-years of methotrexate and/or etanercept treatment in children with polyarticular or systemic juvenile rheumatoid arthritis
por: Giannini, EH, et al.
Publicado: (2008)

Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate
por: Lovell, Daniel J, et al.
Publicado: (2020)

Effectiveness of adalimumab in the treatment of juvenile idiopathic arthritis associated with uveitis
por: Zholobova, Elena, et al.
Publicado: (2014)

2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension
por: Ruperto, N, et al.
Publicado: (2008)

Long term efficacy and safety of canakinumab in children with systemic juvenile idiopathic arthritis with and without fever
por: Horneff, G, et al.
Publicado: (2015)

Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
por: Burmester, Gerd R, et al.
Publicado: (2013)

Canakinumab treatment shows maintained efficacy in systemic juvenile idiopathic arthritis patients
por: Wulffraat, NM, et al.
Publicado: (2014)

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
por: Ruperto, N, et al.
Publicado: (2014)

Rilonacept (IL-1 TRAP) for treatment of colchicine resistant familial mediterranean fever (FMF): a randomized, multicenter double-blinded, alternating treatment trial
por: Hashkes, PJ, et al.
Publicado: (2011)

Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results
por: Brunner, Hermine I., et al.
Publicado: (2020)

The Pathology of Suppuration in the Nasal Accessory Sinuses and Its Relationship to Nasal Polypus
por: McIlraith, Charles H.
Publicado: (1899)

The Pathology of Suppuration in the Nasal Accessory Sinuses and Its Relationship to Nasal Polypus
por: McIlraith, Charles H.
Publicado: (1899)

Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study
por: De Benedetti, F, et al.
Publicado: (2014)

Continuous cardiac pacing for 53 years
por: McIlraith, Bridget, et al.
Publicado: (2022)

3.5 Comparison of functional ability in juvenile idiopathic arthritis, juvenile dermatomyositis, juvenile systemic lupus erythematosus and healthy controls. An analysis of the PRINTO database
por: Filocamo, G, et al.
Publicado: (2008)

Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Minoia, Francesca, et al.
Publicado: (2014)

Abatacept treatment improves health-related quality of life, pain, and sleep quality in juvenile idiopathic arthritis patients
por: Ruperto, N, et al.
Publicado: (2008)

Reduction in missed school days and improvement in parent activity participation in children with juvenile idiopathic arthritis treated with abatacept
por: Ruperto, N, et al.
Publicado: (2008)

Efficacy and safety of canakinumab, a long acting fully human anti-Interleukin-1β antibody, in systemic juvenile idiopathic arthritis with active systemic features: results from a phase III study
por: Ruperto, N, et al.
Publicado: (2011)

Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial
por: Ruperto, Nicola, et al.
Publicado: (2014)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

Towards the Role of Theory of Mind in Explanation
por: Shvo, Maayan, et al.
Publicado: (2020)

Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis
por: Davì, Sergio, et al.
Publicado: (2011)

PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH
por: De Benedetti, F, et al.
Publicado: (2013)

Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
por: Minden, Kirsten, et al.
Publicado: (2014)

PReS-FINAL-2194: Evidence-based clinical classification criteria for periodic fevers
por: Federici, S, et al.
Publicado: (2013)

Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
por: Joos, R, et al.
Publicado: (2011)

OR7-004 – Validation of AIDAI score
por: Piram, M, et al.
Publicado: (2013)

Defining clinical remission and clinically inactive disease in juvenile systemic lupus erythematosus (jSLE)
por: Mina, Rina, et al.
Publicado: (2011)

Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
por: Kingsbury, Daniel J., et al.
Publicado: (2014)

Long-term methotrexate efficacy in juvenile localized scleroderma
por: Zulian, F, et al.
Publicado: (2011)

Current Medical Treatments for Juvenile Idiopathic Arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2011)

Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
por: Imagawa, Tomoyuki, et al.
Publicado: (2012)

PReS-FINAL-2184: A randomized trial in new onset juvenile dermatomyositis: prednisone versus prednisone plus cyclosporine versus prednisone plus methotrexate
por: Ruperto, N, et al.
Publicado: (2013)

Chronic Recurrent Multifocal Osteomyelitis (CRMO) and Juvenile Spondyloarthritis (JSpA): To What Extent Are They Related?
por: Koné-Paut, Isabelle, et al.
Publicado: (2023)

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic Juvenile Idiopathic arthritis (sJIA)
por: Ruperto, N, et al.
Publicado: (2008)

Time to diagnosis in juvenile idiopathic arthritis: a french perspective
por: Aoust, Laura, et al.
Publicado: (2017)

The effects of early aggressive therapy in JIA: results of the TREAT study
por: Wallace, Carol A, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_442knv2p37ld7pf9ifodaedur5